Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1276 to 1290 of 1422 results for social care

  1. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

    Discontinued [GID-TA10569]

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued [GID-TA11000]

    Technology appraisal guidance
    Discontinued

  3. Omburtamab for treating relapsed neuroblastoma [ID1664]

    In development [GID-TA10608] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued [GID-TA10264]

    Technology appraisal guidance
    Discontinued

  5. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    Discontinued [GID-TA10996]

    Technology appraisal guidance
    Discontinued

  6. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued [GID-TA10337]

    Technology appraisal guidance
    Discontinued

  7. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

    Technology appraisal guidance
    Last updated
    2 July 2021
    View recommendations

    Sections for TA355

  8. Roflumilast for treating chronic obstructive pulmonary disease (TA461)

    Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease in adults with chronic bronchitis.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA461

  9. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued [GID-TA10452]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma [ID1610]

    Discontinued [GID-TA10499]

    Technology appraisal guidance
    Discontinued

  11. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued [GID-TA10633]

    Technology appraisal guidance
    Discontinued

  12. Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

    Discontinued [GID-HST10019]

    Highly specialised technologies guidance
    Discontinued

  13. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued [GID-TA11004]

    Technology appraisal guidance
    Discontinued

  14. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    In development [GID-TA10597] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

    Technology appraisal guidance
    Discontinued